Company type | L.L.C. |
---|---|
Industry | Radiopharmaceutical |
Founded | June 2010 |
Founder | Gregory Piefer |
Headquarters | |
Key people | |
Website | www |
Shine Technologies (stylized as SHINE Technologies) is a private corporation based in Janesville, Wisconsin. The company applies nuclear fusion and advanced separation technologies across fields of critical need, including nondestructive testing, radiation hardening services for industrial and defense applications, and the production of radioisotopes, including n.c.a. lutetium-177 for cancer treatment.
SHINE is also engaged in research and development for recycling nuclear fuel, and aspires to produce economical fusion energy resulting from continuous reinvestment of a portion of its earnings from earlier phase businesses. SHINE's key differentiator versus other fusion companies is that its business model is focused on achieving economic breakeven for fusion, rather than scientific or engineering breakeven for fusion energy.
SHINE Technologies originated from Phoenix Nuclear Labs, founded by Dr. Gregory Piefer in 2005. The company was founded on the idea that the fastest path to achieving economically viable fusion energy was to commercialize near-term applications that allowed for improvement by practice and reinvestment. Phoenix initially pioneered fusion-based technology for industrial nondestructive testing, establishing a foundation in solid and then gas-target neutron generation with the goal to increase target temperature over time that will lead to more efficient fusion yields. [2] [3]
In 2010, SHINE Medical Technologies was spun off, focusing on medical isotope production using fusion technology. [4]
In 2013, SHINE Technologies constructed a full-scale prototype fusion device at its Monona, Wisconsin facility, proving the feasibility of its fusion neutron generator. [5]
An independent validation by Argonne National Laboratory in June 2015 confirmed that SHINE's production, separation, and purification process could generate Mo-99, meeting strict purity standards of the British Pharmacopoeia. [6] [7] [8]
In 2016, the Nuclear Regulatory Commission (NRC) granted a construction permit for SHINE's Janesville facility, known as the Chrysalis. [9]
In July 2019, SHINE Technologies and Phoenix Nuclear Labs collaboratively set a world record for the strongest sustained nuclear fusion reaction in a steady-state system. [10] [11] [12]
In 2021, SHINE Technologies reacquired Phoenix Nuclear Labs to integrate their fusion technology and isotope production capabilities. This merger marked the transition from SHINE Medical Technologies LLC to SHINE Technologies LLC, reflecting its broader focus within the nuclear technology sector. [13] [14]
In 2023, SHINE Technologies captured the first-ever image of Cherenkov radiation from a commercial fusion device, validating their beam-target fusion technology and attracting additional investment. [15]
In 2023, the NRC issued both its final supplemental environmental impact statement and Final Safety Evaluation Report for the Chrysalis, concluding that there were no safety aspects precluding the issuance of the license for operation. [16]
In 2024, SHINE Technologies submitted a Drug Master File to the FDA for non-carrier-added lutetium-177, a radiopharmaceutical used in precision cancer treatment. [17]
SHINE Technologies plans to produce a range of isotopes, especially focused on those that are produced with neutrons such as Molybdenum-99 (Mo-99), which is used to create Tc-99m for diagnostic scans. SHINE's fusion-driven Mo-99 production technology expects to reduce nuclear waste and improve reliability compared to traditional methods. This approach uses fusion-driven sub-critical targets and allows for the reuse of low-enriched uranium. SHINE's Chrysalis facility incorporates multiple production systems to ensure continued supply of radioisotopes even if one accelerator is offline. [18] [8]
SHINE also produces n.c.a. Lutetium-177, a radioactive isotope used in targeted cancer therapy and its precursor material ytterbium-176 (Yb-176). In 2024, SHINE submitted a Drug Master File to the FDA for n.c.a. Lu-177 and opened Cassiopeia, North America's largest Lu-177 processing facility, with an initial production capacity of 100,000 doses per year, expandable to 200,000 doses. Producing Lu-177 in North America reduces transit times and minimizes decay losses during shipping. [19] [20] [21] Today, SHINE uses neutrons from external reactors to irradiate Yb-176, but anticipates that it will switch to internal sources as its Chrysalis facility comes online. [22] [23]
SHINE Technologies offers FLARE (Fusion Linear Accelerator for Radiation Effects Testing), providing high fluence 14 MeV neutrons for testing the reliability of components under radiation. This service is used in various fusion technology applications including materials validation and breeder blanket development, as well as defense and commercial rad-hardness testing. [24] [25]
SHINE Technologies operates several facilities:
SHINE Technologies employs a four-phased business strategy aimed at leveraging current fusion technology for revenue generation and reinvestment that enable steady and sustainable progress towards commercial fusion energy. [30]
Tritium or hydrogen-3 is a rare and radioactive isotope of hydrogen with half-life ~12.3 years. The nucleus of tritium contains one proton and two neutrons, whereas the nucleus of the common isotope hydrogen-1 (protium) contains one proton and no neutrons, and that of a non-radioactive hydrogen-2 (deuterium) contains one proton and one neutron.
Enriched uranium is a type of uranium in which the percent composition of uranium-235 has been increased through the process of isotope separation. Naturally occurring uranium is composed of three major isotopes: uranium-238, uranium-235, and uranium-234. 235U is the only nuclide existing in nature that is fissile with thermal neutrons.
Fusion power is a proposed form of power generation that would generate electricity by using heat from nuclear fusion reactions. In a fusion process, two lighter atomic nuclei combine to form a heavier nucleus, while releasing energy. Devices designed to harness this energy are known as fusion reactors. Research into fusion reactors began in the 1940s, but as of 2024, no device has reached net power, although net positive reactions have been achieved.
Nuclear technology is technology that involves the nuclear reactions of atomic nuclei. Among the notable nuclear technologies are nuclear reactors, nuclear medicine and nuclear weapons. It is also used, among other things, in smoke detectors and gun sights.
Argonne National Laboratory is a federally funded research and development center in Lemont, Illinois, United States. Founded in 1946, the laboratory is owned by the United States Department of Energy and administered by UChicago Argonne LLC of the University of Chicago. The facility is the largest national laboratory in the Midwest.
The nuclear fuel cycle, also called nuclear fuel chain, is the progression of nuclear fuel through a series of differing stages. It consists of steps in the front end, which are the preparation of the fuel, steps in the service period in which the fuel is used during reactor operation, and steps in the back end, which are necessary to safely manage, contain, and either reprocess or dispose of spent nuclear fuel. If spent fuel is not reprocessed, the fuel cycle is referred to as an open fuel cycle ; if the spent fuel is reprocessed, it is referred to as a closed fuel cycle.
A radioligand is a microscopic particle which consists of a therapeutic radioactive isotope and the cell-targeting compound - the ligand. The ligand is the target binding site, it may be on the surface of the targeted cancer cell for therapeutic purposes. Radioisotopes can occur naturally or be synthesized and produced in a cyclotron/nuclear reactor. The different types of radioisotopes include Y-90, H-3, C-11, Lu-177, Ac-225, Ra-223, In-111, I-131, I-125, etc. Thus, radioligands must be produced in special nuclear reactors for the radioisotope to remain stable. Radioligands can be used to analyze/characterize receptors, to perform binding assays, to help in diagnostic imaging, and to provide targeted cancer therapy. Radiation is a novel method of treating cancer and is effective in short distances along with being unique/personalizable and causing minimal harm to normal surrounding cells. Furthermore, radioligand binding can provide information about receptor-ligand interactions in vitro and in vivo. Choosing the right radioligand for the desired application is important. The radioligand must be radiochemically pure, stable, and demonstrate a high degree of selectivity, and high affinity for their target.
The integral fast reactor (IFR), originally the advancedliquid-metal reactor (ALMR), is a design for a nuclear reactor using fast neutrons and no neutron moderator. IFRs can breed more fuel and are distinguished by a nuclear fuel cycle that uses reprocessing via electrorefining at the reactor site.
The Petten High Flux Reactor (HFR) is a nuclear research reactor located in Petten, Netherlands. The HFR is on the premises of the Petten research centre and it is a high flux reactor. It is owned by the Joint Research Centre (JRC) and managed by the Nuclear Research and Consultancy Group (NRG). The HFR’s original purpose was to provide experience and irradiation capabilities for the nascent Dutch nuclear power program. Construction began in 1958, and the reactor reached criticality on the 9th of November, 1961.
The Bhabha Atomic Research Centre (BARC) is India's premier nuclear research facility, headquartered in Trombay, Mumbai, Maharashtra, India. It was founded by Homi Jehangir Bhabha as the Atomic Energy Establishment, Trombay (AEET) in January 1954 as a multidisciplinary research program essential for India's nuclear program. It operates under the Department of Atomic Energy (DAE), which is directly overseen by the Prime Minister of India.
The National Research Universal (NRU) reactor was a 135 MW nuclear research reactor built in the Chalk River Laboratories, Ontario, one of Canada’s national science facilities. It was a multipurpose science facility that served three main roles. It generated radionuclides used to treat or diagnose over 20 million people in 80 countries every year. It was the neutron source for the NRC Canadian Neutron Beam Centre: a materials research centre that grew from the Nobel Prize-winning work of Bertram Brockhouse. It was the test bed for Atomic Energy of Canada Limited to develop fuels and materials for the CANDU reactor. At the time of its retirement on March 31, 2018, it was the world's oldest operating nuclear reactor.
The International Fusion Materials Irradiation Facility, also known as IFMIF, is a projected material testing facility in which candidate materials for the use in an energy producing fusion reactor can be fully qualified. IFMIF will be an accelerator-driven neutron source producing a high intensity fast neutron flux with a spectrum similar to that expected at the first wall of a fusion reactor using a deuterium-lithium nuclear reaction. The IFMIF project was started in 1994 as an international scientific research program, carried out by Japan, the European Union, the United States, and Russia, and managed by the International Energy Agency. Since 2007, it has been pursued by Japan and the European Union under the Broader Approach Agreement in the field of fusion energy research, through the IFMIF/EVEDA project, which conducts engineering validation and engineering design activities for IFMIF. The construction of IFMIF is recommended in the European Roadmap for Research Infrastructures Report, which was published by the European Strategy Forum on Research Infrastructures (ESFRI).
Bruce Power Limited Partnership is a Canadian business partnership composed of several corporations. It exists as a partnership between TC Energy (31.6%), BPC Generation Infrastructure Trust (61.4%), the Power Workers Union (4%) and The Society of United Professionals (1.2%). It is the licensed operator of the Bruce Nuclear Generating Station, located on the shores of Lake Huron, roughly 250 kilometres northwest of Toronto, between the towns of Kincardine and Saugeen Shores. It is the third-largest operating nuclear plant in the world by capacity.
Technetium-99m (99mTc) is a metastable nuclear isomer of technetium-99, symbolized as 99mTc, that is used in tens of millions of medical diagnostic procedures annually, making it the most commonly used medical radioisotope in the world.
Reactor-grade plutonium (RGPu) is the isotopic grade of plutonium that is found in spent nuclear fuel after the uranium-235 primary fuel that a nuclear power reactor uses has burnt up. The uranium-238 from which most of the plutonium isotopes derive by neutron capture is found along with the U-235 in the low enriched uranium fuel of civilian reactors.
A neutron research facility is most commonly a big laboratory operating a large-scale neutron source that provides thermal neutrons to a suite of research instruments. The neutron source usually is a research reactor or a spallation source. In some cases, a smaller facility will provide high energy neutrons using existing neutron generator technologies.
The Pakistan Atomic Research Reactor or (PARR) are two nuclear research reactors and two other experimental neutron sources located in the PINSTECH Laboratory, Nilore, Islamabad, Pakistan.
Nuclear transmutation is the conversion of one chemical element or an isotope into another chemical element. Nuclear transmutation occurs in any process where the number of protons or neutrons in the nucleus of an atom is changed.
Phoenix, formerly known as Phoenix Nuclear Labs, is a company specializing in neutron generator technology located in Monona, Wisconsin. Founded in 2005, the company develops nuclear and particle accelerator technologies for application in medicine, defense and energy. Phoenix has held contracts with the U.S. Army, the U.S. Department of Energy, the U.S. Department of Defense and the U.S. Air Force. Phoenix developed a proprietary gas target neutron generator technology and has designed and built a number of particle accelerator-related technologies.
Radioisotopes Production Facility (RPF), is a facility for the production of radioisotopes from irradiation of Low enriched uranium (LEU) in the Egyptian Second Research Reactor (ETRR-2) Complex. The RPF was supplied by the Argentine company Investigacion Aplicada (INVAP) and was commissioned during October and November 2011. The produced radioisotopes are used in medicine, industry and research activities for domestic market.
{{cite journal}}
: CS1 maint: date format (link)